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Abstract: The SARS-CoV-2 main protease (Mpro) is one of the molecular targets for drug design.
Effective vaccines have been identified as a long-term solution but the rate at which they are be-
ing administered is slow in several countries, and mutations of SARS-CoV-2 could render them
less effective. Moreover, remdesivir seems to work only with some types of COVID-19 patients.
Hence, the continuous investigation of new treatments for this disease is pivotal. This study inves-
tigated the inhibitory role of natural products against SARS-CoV-2 Mpro as repurposable agents
in the treatment of coronavirus disease 2019 (COVID-19). Through in silico approach, selected
flavonoids were docked into the active site of Mpro. The free energies of the ligands complexed with
Mpro were computationally estimated using the molecular mechanics-generalized Born surface area
(MM/GBSA) method. In addition, the inhibition process of SARS-CoV-2 Mpro with these ligands
was simulated at 100 ns in order to uncover the dynamic behavior and complex stability. The docking
results showed that the selected flavonoids exhibited good poses in the binding domain of Mpro.
The amino acid residues involved in the binding of the selected ligands correlated well with the
residues involved with the mechanism-based inhibitor (N3) and the docking score of Quercetin-3-O-
Neohesperidoside (−16.8 Kcal/mol) ranked efficiently with this inhibitor (−16.5 Kcal/mol). In addi-
tion, single-structure MM/GBSA rescoring method showed that Quercetin-3-O-Neohesperidoside
(−87.60 Kcal/mol) is more energetically favored than N3 (−80.88 Kcal/mol) and other ligands
(Myricetin 3-Rutinoside (−87.50 Kcal/mol), Quercetin 3-Rhamnoside (−80.17 Kcal/mol), Rutin
(−58.98 Kcal/mol), and Myricitrin (−49.22 Kcal/mol). The molecular dynamics simulation (MDs)
pinpointed the stability of these complexes over the course of 100 ns with reduced RMSD and RMSF.
Based on the docking results and energy calculation, together with the RMSD of 1.98 ± 0.19 Å
and RMSF of 1.00 ± 0.51 Å, Quercetin-3-O-Neohesperidoside is a better inhibitor of Mpro compared
to N3 and other selected ligands and can be repurposed as a drug candidate for the treatment of
COVID-19. In addition, this study demonstrated that in silico docking, free energy calculations, and
MDs, respectively, are applicable to estimating the interaction, energetics, and dynamic behavior
of molecular targets by natural products and can be used to direct the development of novel target
function modulators.
Keywords: flavonols; SARS-CoV-2; Mpro; natural products; MDs; MM/GBSA; docking; COVID-19;
in silico approach; protein-ligand interaction; antiviral agents
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1. Introduction
Viral infection is one of the major challenges faced by human health, and many viral
diseases are correlated with high morbidity and mortality rates in humans. Previously, viral
diseases such as influenza, dengue, HIV, and coronaviruses have resulted in epidemics or
global pandemics, claiming many lives. Currently, the world is battling with coronavirus
diseases 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) which has resulted in approximately 4 million deaths as of July 2021. The
emergence of variants of this disease has also been challenging to the developed vaccines,
and, as it stands, there are no effective therapeutic interventions against this disease.
Proteins associated with viral infection can serve as molecular targets for disease prevention
and treatment. Molecules involved in viral DNA replication and protein synthesis can be
pivotal to these processes. Targets such as Papain-like protease (PLpro), 3-chymotrypsin
like protease (3CLPro) also called main protease (Mpro), RNA-dependent RNA polymerase
(RdRp), and helicase have been reported as potential points of treatment development for
SARS-CoV-2 infection [1–3]. The SARS-CoV-2 spike protein and angiotensin-converting
enzyme-2 (ACE-2) were also identified as promising targets for disease prevention [4–6].
The non-structural proteins essential for the replication of viral particles are specifically
generated by PLpro and Mpro, defining their roles in viral replication and outlining their
inhibition as potential anti-SARS-CoV-2 treatments [7–9].
Biologically active molecules have been screened against Mpro as either repurposed
drugs or in the process of lead identification. Muhammad et al. [10] screened a library of
phytochemicals against Mpro and revealed the potential usage of molecules from natural
sources as anti-COVID-19 druggable candidates. In another study, bioactive medicinal
plants were assayed against Mpro using in silico docking and pharmacological screen-
ing. Selected molecules from alkaloids and terpenoids were identified as inhibitors of
this target, with a highly conserved inhibitory pattern to both SARS-CoV-2 and SARS-
CoV [11]. Moreover, nucleopeptides and Opuntia-derived phytochemicals were suggested
as Mpro potential inhibitors [12,13]. Therefore, the inhibition of protein activity of Mpro
may potentially suppress coronavirus transmission.
Natural products of low molecular weight from plant sources are potent therapeutic
agents for many diseases and some of these agents possess antiviral properties. While
many natural products are fundamentally utilized as crude extracts, the purification of
their active ingredients is essential for the prediction of their properties associated with the
pharmacokinetics and pharmacodynamics of a drug molecule.
Accumulating evidence suggests that plant chemicals, for example, polyphenols and
their functional derivatives such as flavonoids, saponins, and lignans can alter cellular func-
tions, membrane permeability, and viral replication [14]. The role of phytochemicals has
also been implicated in cell migration and proliferation, metabolism regulation (phytosterol,
flavanols, anthocyanidins, cinnamic acids, etc.) [15,16], inflammatory processes (quercetin,
kaempferol, etc.) [17], redox modulation (phenolics, curcumin, resveratrol, etc.) [18,19],
and angiogenesis (astaxanthin) [20]. Ethanolic extract of Ficus benjamina has been shown to
contain some active compounds such as rutin, kaempferol 3-O-rutinoside, and kaempferol
3-O-robinobioside, which were effective against herpes simplex [21]. Equally, the phyto-
chemicals homolycorine and 2-O-acetyllycorine isolated from Leucojum vernum were shown
to be effective against HIV-1 [22]. Rutin is a glycosylated flavonoid with a 3-rutinoside
substitution. Its antiviral activity has been studied against avian influenza virus [23],
herpes simplex [21], and parainfluenza-3 virus [24].
The world population is largely dependent on therapies from plant origin [25]. Com-
pounds isolated from this source have little or no side effects with high biological specificity,
chemical diversity, and targets multiple host sites by diverse pathways with negligible
cost [26]. It was previously demonstrated that flavonoids, among other active compounds
from plant sources, have been used for the treatment of HIV, herpes simplex, and influenza
viruses, due to their antiviral properties [27]. These compounds inhibit viral replica-
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tion, proteases, and reverse transcription [28]. Compounds such as quercetin, rutin, and
myricetin have also been identified with similar properties [29].
In this study, five glycosylated flavonoids, belonging to the class of Flavonol, were
selected to evaluate the inhibitory process of SARS-CoV-2 Mpro. These compounds include
Quercetin 3-Rhamnoside, Quercetin-3-O-Neohesperidoside Myricetin 3-Rutinoside, Rutin,
and Myricitrin. The mode of antiviral action of Quercetin 3-Rhamnoside, a phytochemical
derived from Houttuynia cordata (Aerial parts), is by targeting influenza A/WS/33 virus
through the inhibition of replication in the early stage of viral infection by indirect inter-
action with virus particles [30]. The major active compound of Trollius ledebouri Reichb., a
popular medicinal plant in China, known to possess antibacterial and antiviral activities
used in the treatment of acute myringitis, cold, sore throat, and fever, is Quercetin-3-
O-Neohesperidoside [31,32]. Pharmacological Screening suggests that this compound
possesses activity against inflammation [33]. Myricetin and its derivatives derived from
Myricaceae are known for their nutraceuticals value with activities including anticancer,
antioxidant, anti-inflammatory, and antidiabetic [34]. Flavonoids, such as Myricitrin,
Quercetin, and Kaempferol, are structurally related to Myricetin [35]. Myricetin differs
from Myricitrin in that the hydrogen atom of Myricetin at carbon 3 of the C-ring is substi-
tuted with rhamnose. At this same position, rutinoside can be substituted to form Myricetin
3-Rutinoside. Properties of Myricetin against bacteria and viruses were established by
Cai, et al. [36]. Recently, the antiviral property of Myricetin and Myricitrin was demon-
strated against swine fever virus protease. In the study, 65 flavonoids were screened against
the swine fever viral protease using the fluorescence resonance energy transfer method.
Myricetin and Myricitrin showed inhibitory potential against the target, suggesting their
role in the development of anti-swine fever virus agents based on their scaffold [37]. Rutin
is otherwise known as rutoside or quercetin-3-O-rutinoside. Structurally, this glycosylated
flavonoid consists of rutinose linked to Quercetin. The neuroprotective properties of this
flavonoid were reported against a cisplatin-induced neurotoxic rat model. Rutin was able
to restore the expression levels of PON-1, PON-2, PON-3, PPAR-δ, and GPX to normal
after being dysregulated by cisplatin [38]. In another study, the anticancer effect of rutin
on breast cancer (BC) was evaluated by in silico and Western blot approaches. The study
concluded that rutin targets c-Met kinase and in turn reduces tumor size and inhibits cell
proliferation, migration, and invasion in BC [39].
The availability of the resolved structures of the essential protein components of
this disease has improved the search for effective therapeutic molecules through in silico
approaches. Molecular docking calculations have gained enormous attention in the search
for novel bioactive molecules and other discovery projects. This approach is an alternative
to experimental techniques due to its speed and accuracy to predict both the binding
affinities and poses of ligands within molecular targets. The prediction accuracy of docking
algorithms can suggest bioactive compounds with higher true positive rates which can, in
turn, reduce experimental challenges [40]. Therefore, the identification of antiviral drugs to
combat infectious diseases can be dependent on the investigation of available compounds
from natural origin with antiviral properties [41]. With limited therapeutic options for the
treatment of COVID-19, five antiviral glycosylated flavonoids were screened against one of
the most essential components of SARS-CoV-2 to investigate their inhibitory role against
the SARS-CoV-2 main protease.
2. Results
Lead discovery strategies consist of screening low molecular weight compounds
(ligands) against biological targets with clinical relevance. Molecular docking is an essential
approach for drug design, most especially in the identification of lead or hit agents. In this
study, the inhibitory role of five natural products (glycosylated flavonoids) was queried
against Mpro in order to ascertain their therapeutic properties against COVID-19. As it
stands, there is no 100% safe vaccine, and effective therapeutic agents are far from being
discovered against this deadly disease.
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2.1. ADME/Tox Prediction
The pharmacokinetics and toxicological properties of the ligands (Tables 1 and 2) were
analyzed according to previous methods to investigate how molecules can access the target
site of Mpro after entering the bloodstream. This analysis is also crucial for analyzing the
efficacy of molecules [42,43]. All parameters were within the ROF cut-off range for the
test compounds and present no bystander toxicity effects since toxicity is the main task in
developing new medications. Ames toxicity, carcinogenic properties, and rat acute toxicity
were predicted in the current investigation.
Table 1. Properties of the selected compounds.
Compound ID a M.W b ROF c QplogHERG d QplogPoW e QplogKP f Donor HB Acceptor HB QplogS g QplogBB h
Quercetin 3-O-
Neohesperidoside 5748416 610.5 2 −6.449 −1.998 −6.423 9 20.55 −2.932 −4.728
Myricetin
3-Rutinoside 44259428 626.5 2 −6.394 −2.455 −5.583 10 21.3 −2.341 −4.306
Quercetin
3-Rhamnoside 5353915 448.3 2 −5.451 −0.55 −6.101 6 12.05 −3.196 −3.312
Rutin 5280805 610.5 2 −5.238 −2.495 −7.251 9 20.55 −2.175 −4.503
Myricitrin 5281673 464.3 2 −5.463 −1.045 −6.589 7 12.8 −2.779 −3.48
a Compound ID from PubChem database. b Formula weight of the compounds (acceptable range: 130.0–725 g/mol). c Number of
permissible violations of Lipinski’s rule of five (acceptable range: maximum is 4). d Predicted IC50 value for blockage of HERG K+ channels
(concern below −5.0). e Predicted octanol/water partition coefficient log p (acceptable range: −2.0 to 6.5). f Predicted skin permeability, log
Kp (acceptable range: −8.0 to −1.0). g Predicted aqueous solubility; S in mol/L (acceptable range: −6.5 to 0.5). h Predicted brain/blood
partition coefficient (acceptable range: −3.0 to 1.2). Donor HB (≤10); Acceptor HB (≤5).
Table 2. Toxicity analysis of the selected compounds predicted by AdmetSAR.
Compound ID AmesToxicity Carcinogens Acute Oral Toxicity Rat Acute Toxicity
Quercetin 3-O-Neohesperidoside 5748416 AT NC III 2.2619
Myricetin 3-Rutinoside 44259428 NAT NC III 2.4984
Quercetin 3-Rhamnoside 5353915 NAT NC III 2.5458
Rutin 5280805 NAT NC III 2.4984
Myricitrin 5281673 NAT NC III 2.5458
Note: AT: Ames toxic NAT: Non Ames toxic; NC: Non-carcinogenic; Category-III means (500 mg/kg > LD50 < 5000 mg/kg).
2.2. Docking Calculations
The protein-ligand interactions for all the complexes after the docking procedure
were produced by Proteins Plus at https://proteins.plus/ (accessed on 1 August 2021)
as depicted in Figure 1. The model representation of the best pose against decoy poses
was also presented using Mpro-Quercetin-3-O-Neohesperidoside (Figure 2). The binding
properties, such as the scoring functions of Autodock Vina and MM/GBSA, the number of
hydrogen bond integrations, and types of residues and their distances (Å) are tabulated
in Table 3. In addition, the possible residue interaction crucial to the inhibition process of
Mpro by these flavonoids was proposed in Figure 3.
Table 3. Binding energies of flavonoids docked against Mpro.
Name Dock Score ∆G Bind H-Bond Residues (Å) Other Bond (Å)
Standard −16.5 −80.88 6 CYS145 (2.13), LEU141 (2.76), PHE140 (2.02), GLU166(1.68,1.83, 2.05) Salt bridges (2)
Quercetin 3-O-
Neohesperidoside −16.8 −87.60 5





3-Rutinoside −12.9 −87.50 7
CYS145 (2.08), ASN142 (1.75), GLU166 (1.98), THR190 (2.21),
ARG188 (1.97), HIS164 (1.90,1.98)
Quercetin
3-Rhamnoside −10.3 −80.17 4 LEU141 (1.49), THR190 (1.78), GLU166 (2.01), HIS164 (1.81)
Rutin −10.0 −58.95 6 THR190 (1.83), HIS41 (2.08), GLY143 (2.39,1.89), ASN142 (1.92),LEU141 (2.10) -
Myricitrin −9.1 −49.22 3 CYS145 (2.51), ASN142 (2.04), THR190 (1.83) π-π stackingHIS41 (5.37)
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Figure 1. 2-dimentional protein–ligand interactions created for docked ligands and N3 into the active site of Mpro ranked
according to their binding energies. Black bond interactions showed H-bonds between the atoms of the ligands and the
residues of the receptor.
Figure 2. Molecular docking of the ligands into Mpro binding site. (A) the docking of the selected
ligands in Mpro binding pocket; (B) Quercetin-3-O-Neohesperidoside seats perfectly in the Mpro
binding pocket; (C) interacting atoms of Quercetin-3-O-Neohesperidoside and Mpro residues in the
binding pocket. Note: blue lines indicate hydrogen bond interaction; green dotted lines indicate
pi-stacking, while gray dotted lines depict hydrophobic interactions.
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Figure 3. Atomic interaction of flavonoids with Mpro residues. While several residues form hydrophobic interactions with
the ligands, other interactions such as hydrogen, π-cation, and π-π stacking were also involved in the inhibition mechanism
of Mpro.
2.3. Molecular Dynamic Simulation
To associate structural and mechanistic information with experimental data, the MDs
were carried out. The Mpro-ligand complexes were computationally simulated for 100 ns
to decipher the complex stability and dynamic behavior as presented in Figures 4–6, and
Table 2. The root-mean-square deviation (RMSD) of the five ligands were plotted against
1000 frame indexes for 100 ns (Figure 4a). The root-mean-square fluctuation (RMSF) of
the C-alpha of the protein complexed with these ligands was also plotted against residues
(Figure 4b). The ligand properties were also taken into account by plotting the radius of
gyration (rGyr) for all five complexes against the frame index over the 100 ns simulation
time (Figure 5). The simulation properties were calculated as the mean ± SD for RMSD,
RMSF, and rGyr (Table 4). Finally, protein interactions with the ligands were monitored
throughout the simulation. These interactions were categorized by type and summarized
as shown in Figure 6.
Table 4. The simulation properties of the complexes.
Properties A B C D E
RMSD 1.98 ± 0.19 2.25 ± 0.26 3.05 ± 0.57 1.81 ± 0.30 2.26 ± 0.51
RMSF 1.00 ± 0.51 1.31 ± 0.55 1.27 ± 0.58 1.15 ± 0.58 1.25 ± 0.65
rGyr 5.03 ± 0.09 4.96 ± 0.03 4.57 ± 0.05 5.15 ± 0.10 6.09 ± 0.09
Values represent the mean ± SD of 1000 frame index replicates. Letter codes: Quercetin-3-O-Neohesperidoside
(A), Quercetin 3-Rhamnoside (B), Myricitrin (C), Rutin (D), and Myricetin 3-Rutinoside (E). Values are in Å.
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Figure 4. Stability and flexibility of the selected flavonoid derivatives complexed with Mpro over the
course of 100 ns. (A) is the RMS deviation and (B) is the RMS functions of the Cα of each complexes.
Color codes denote: Quercetin-3-O-Neohesperidoside (A), Quercetin 3-Rhamnoside (B), Myricitrin
(C), Rutin (D), and Myricetin 3-Rutinoside (E).
Figure 5. Radius of gyration (rGyr) plot for Mpro and the selected flavonoid derivatives within the
simulation time of 100 ns. Color codes denote: Quercetin-3-O-Neohesperidoside (A), Quercetin
3-Rhamnoside (B), Myricitrin (C), Rutin (D), and Myricetin 3-Rutinoside (E).
Figure 6. Observed Mpro-ligands interaction during the 100 ns MD simulation. Interactions include;
hydrogen bonds, hydrophobic, ionic and water bridges. Letter codes indicate: Quercetin-3-O-
Neohesperidoside (A), Quercetin 3-Rhamnoside (B), Myricitrin (C), Rutin (D), and Myricetin 3-
Rutinoside (E).
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3. Discussion
Biologically active molecules from natural sources have been explored for their use
in the treatment of diseases. The relationship between secondary metabolites and disease
prevention has been a focal point in medicine. Growing knowledge of disease pathogen-
esis and molecular targets by small molecules from natural products may provide novel
strategies to prevent or manage various diseases. With various challenges associated with
various discovered vaccines, coupled with limited therapeutic options against COVID-19,
in silico approaches may be employed to source effective compounds against SARS-CoV-2
macromolecules. Compounds with antiviral properties have been isolated and purified
from plant origin [44], some of which possess numerous advantages that assist in inhibiting
viral replication, viral penetration in the host cell [45]. Docking approaches primarily
identify correct ligand orientations and accurately predict binding affinities.
3.1. Drug-Likeness (ADME/Tox) Analysis
Lipinski’s ROF was designed to set guidelines for the drugability of compounds. The
efficacy of drug candidate does not directly correlate with Lipinski’s rule of five for disease
treatment and meeting these criteria does not ascertain drug-likeness [46]. However, chal-
lenges associated with oral activities may arise for Lipinski’s violation [47]. The Lipinski’s
parameters are closely associated with oral bioavailability, intestinal permeability and
acceptable aqueous solubility [42]. The selected glycosylated flavonoids are in agreement
with the oral drugability and bioavailability of Lipinski’s rule of five criteria. Veber’s rule
suggests that compounds with hydrogen bond acceptors and donors ≤ 12 have better oral
bioavailability [48]. Quercetin-3-O-Neohesperidoside, Quercetin 3-Rhamnoside, Myricitrin,
Rutin, and Myricetin 3-Rutinoside were all predicted to meet the majority of the criteria for
an orally active drug molecule.
3.2. Docking Analysis
The docking program Autodock Vina was used to produce different poses of the
ligands and further rank these ligands based on their scoring function. This software
was able to pinpoint the native docking pose among the decoy poses and further pre-
dicted the binding affinities of the ligands based on the scoring power. Mpro-N3 was
ranked second highest based on the negative binding energy of −16.5 Kcal/mol, while
Myricitrin was ranked lowest with −9.1 Kcal/mol. The intermolecular interaction of
Quercetin-3-O-Neohesperidoside as a model was ranked first with a binding energy of
−16.8 Kcal/mol. A similar study reported lower negative energy (−8 kcal/mol) for
Quercetin-3-O-Neohesperidoside as opposed to −16.8 Kcal/mol obtained in this study [49].
The reason for this could be attributed to the method of preparation and minimization of
both the ligand and the receptor, and also the size of the generated grid box before docking.
In actual fact, the bigger the grid box created prior to docking, the more time-consuming
the simulation process which could, in turn, affect the output in terms of binding score.
The scoring function of docking calculation provides a quick but crude estimation
of the binding affinity between the ligand and target [50]. During docking calculations,
scoring functions are used to extrapolate the docking poses derived by docking algo-
rithms. These functions facilitate the binding affinities to attain high throughput screen-
ing. It was previously reported that docking calculations often fail to evaluate binding
energy when compared to experimental values [51]. Therefore, the Prime MM/GBSA
software was used to re-score the ligand binding affinities due to its rapid force-field-
based method used for computations [52]. Comparing the dock scores and MM/GBSA
rescoring methods, MM/GBSA provides more accurate results. The MM/GBSA rescoring
ranked the binding affinities in the order: Quercetin 3-O-Neohesperidoside > Myricetin
3-Rutinoside > Quercetin 3-Rhamnoside > Rutin > Myricitrin, to corroborate the docking
scores. Although natural products are sometimes underestimated when compared to
Western medicines, drugs such as paclitaxel aspirin, digitalis, and reserpine with therapeu-
tic efficacy were derived from natural products [53]. With many advantages associated
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with natural products the discoveries of therapeutic compounds deserve the efficacy of
natural sources.
Judging from the number of hydrogen bond interactions exhibited by the ligands,
CYS145, GLU166, HIS41, THR190, and ASN142, play a crucial role in the Mpro binding
process. The most notable interactions involve the carboxyl and amino groups of charged
residues (GLU166, HIS41, and HIS164) and polar residues (ASN142 and CYS145). These
residues provide rich hydrogen bond donors or acceptors between the amino or carboxyl
groups of Mpro and the poly-hydroxyl groups of the ring structures of the ligands. In addi-
tion to the hydrogen bond interactions, Quercetin 3-O-Neohesperidoside and Myricitrin
formed a π-π stacking between the dihdroxylphenyl D aromatic ring and HIS41 residue
of Mpro with a distance of 1.49 and 5.37 Å, respectively. Pi-pi (π-π) stacking and π-cation
interactions are crucial for favorable electron correlation and electrostatic contributions,
respectively [54]. The difference in bond length could also contribute to the reason why
Quercetin 3-O-Neohesperidoside has a higher negative energy compared to Myricitrin.
Protein-ligand interactions are fundamental to biological processes. Ligand interactions
cause conformational changes in both the ligand and protein, which further induces a
series of events resulting in diverse cellular activities [55]. Jin et al. [56], who discovered
the crystal structure of Mpro complexed with N3 using computer-aided software, further
analyzed the Mpro residues involved in binding interactions. Amino acids such as PHE140,
GLN189, GLY143, GLU166, THR190, CYS145, and HIS163 were reported to be crucial in the
inhibition process of Mpro through hydrogen bonding. In addition, several hydrophobic
interactions were also reported.
The possible mechanism of inhibition of SARS-CoV-2 was proposed through residue
linkage and different interactions with poly hydroxyl and oxygen atoms of natural products
using a flavonoid (Quercetin 3-O-Neohesperidoside) as a representative. Although a
number of studies have employed in silico approaches to uncover the interactions between
different receptors and ligands, and have also used similar compounds for different targets,
none of these studies have been able to elucidate or propose the inhibitory mechanism by
which flavonoids and their derivatives interact with their respective targets.
This structure is composed of five aromatic rings (A–E). The parent compound flavonol
(3,4-dihydroxyphenyl-5,7-dihydroxychromen-4-one), consisting of poly hydroxyl groups
at positions A-7 and 5, and B-2 and 4, has the ability to form hydrogen bonds with THR190
and GLU166, respectively. The hydroxyl atoms of Oxyoxane and 6-methyloxane were also
capable of hydrogen linkage with residues such as GLN189, HIS164, CYS145, and GLY143.
π-π stacking was also found in the aromatic B-ring of the parent compound and HIS41.
Other hydrophobic interactions include MET165, ARG188, ASP188, and HIS41. These
multiple interactions may suggest a good binding affinity of flavonoids and other natural
products with targets and further inhibition of their activities.
Gyebi et al. [11] identified the importance of CYS145 and HIS41 as conserved cat-
alytic dyad residues of SARS-CoV-2 Mpro. Interestingly, all of the screened molecules
in this study interacted with one of the two amino acids. The atoms of Quercetin 3-O-
Neohesperidoside and Myricitrin interacted with these residues, suggesting their role as
candidates or leads for drug development against this disease. Natural products with
biological activity, with reference to past events, may be good sources for the synthesis of
drugs with antiviral properties.
3.3. Molecular Dynamic Simulation
MDs were carried out to generate dynamic representation at atomic spatial resolution
for Mpro-ligand complexes for all the studied compounds, and to establish a more reliable
mechanism for illustrating protein interactions with small molecules. After the molecular
docking of the selected glycosylated flavonoids, MDs of the complexes were evaluated
for stability in terms of residue flexibility and bond types over the course of 100 ns. The
stability and structural flexibility of these complexes were studied through RMSD and
RMSF plots, respectively.
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The RMSD is a measure of atomic distances or coordinates, such as the C-alpha
protein backbone. The MD trajectory analysis of the complexes showed that Quercetin
3-Rhamnoside, Myricitrin, and Myricetin 3-Rutinoside are more stable than Rutin over
100 ns of simulation. The obtained RMSD values ranged from 1.81 ± 0.30 to 3.05 ± 0.57 Å.
Rutin had the lowest RMSD (1.81 ± 0.30 Å) followed by Quercetin-3-O-Neohesperidoside
with RMSD of 1.98 ± 0.19 Å. The lower the RMSD the less deviation from the back-
bone and the greater the stability [57]. The stability of these compounds is in the or-
der of Rutin > Quercetin-3-O-Neohesperidoside > Quercetin 3-Rhamnoside > Myricetin
3-Rutinoside > Myricitrin. The slight variations observed may be attributed to complex
conformations [58]. The average deviation of the complexes was monitored by the RMSF
from a reference point over 100 ns. To probe how the molecules affect the dynamics of the
backbone atoms of Mpro, the RMSF values were calculated. The RMSFs of the complexes
were ≤1.31 Å. Quercetin-3-O-Neohesperidoside had the lowest RMSF of 1.00 ± 0.51 Å
followed by Rutin with an RMSF of 1.15 ± 0.58 Å. Quercetin 3-Rhamnoside, Myric-
itrin, and Myricetin 3-Rutinoside had the highest RMSF of 1.31 ± 0.55, 1.27 ± 0.58, and
1.25 ± 0.65 Å, respectively.
Besides the C and N-terminal RMSFs that are expected to fluctuate maximally, fluctua-
tions were observed around the residues 50 and 180. These regions could be loop regions
with additional conformational flexibilities. The RMSF values of the systems relative to
each amino acid residue of the complexes were evaluated to compare the residues’ flexi-
bility. The RMSF reported the flexible region of the complexes and displayed that none
of the important catalytic residues present in the active site region has shown an RMSF
value of more than 1.31 Å. This serves to confirm that the catalytic machinery present in
the Mpro active site was not distorted upon binding of the compounds. The amino acids,
namely, THR26, HIS41, CYS44, SER47, MET49, TYR54, ASN142, GLY143, SER144, CYS145,
HIS164, MET165, GLU166, LEU167, ASP187, THR190, GLN192, ARG217, THR304, and
PHE305 have displayed flexibility upon the binding of the studied compounds. Regardless
of the nature of these residues within the active site of Mpro, they were relatively stable
in complex systems indicating the binding nature of the compounds. With respect to all
these complexes, the residues fluctuate with respect to the nature of the compound in the
active site and types of interacting atoms. Particularly, THR190, GLU16, HIS163, PHE140,
GLY143, CYS145, and GLN189 fluctuated more compared to other amino acids in the
active site indicating their flexible nature and therefore could be a good determinant in the
identification of inhibitory molecules.
The rGyr was used to demonstrates the size and the compactness of the complexes [59]
relative to the RMSD of the protein. Rutin has the lowest average rGyr of 4.57 ± 0.05 Å while
Myricetin 3-Rutinoside has the highest average value of 6.09 ± 0.09 Å. Although the values
of the rGyr for each of the complexes were high, there was no visible fluctuation throughout
the simulation process. According to a study by Cherrak et al. [49], who observed a low
rGyr of 3 natural compounds in the range of 2.2–2.3 nm and did not induce structural
changes in the protein, a high rGyr value in this study could be associated with protein
conformational changes which could alter the normal function of the SARS-CoV-2 Mpro.
In tracking the dynamical changes following protein modification, the possible interac-
tions such as hydrogen bond, hydrophobic interaction, water bridges, and ionic interaction
were studied for the five complexes simulated over a 100 ns period. GLU166 interacted
almost 90% of the entire simulation period between Quercetin-3-O-Neohesperidoside,
Quercetin 3-Rhamnoside, Myricitrin, and Rutin and Mpro using both hydrogen bond and
water bridges. To a lesser extent, Myricetin 3-Rutinoside interacted with this residue
about 20% of the 100 ns. In addition, the number of observable hydrogen bonds of the
ligands in the active site of Mpro is in the order of Quercetin 3-Rhamnoside < Rutin
< Myricitrin < Myricetin 3-Rutinoside < Quercetin-3-O-Neohesperidoside. Hydrogen
bonds, among other interactions, play a pivotal role in the stability of a protein’s sec-
ondary structure. Quercetin 3-O-Neohesperidoside was found to be stable in the active
site of Mpro throughout the 100 ns simulation with an average RMSD of 1.98 ± 0.19 Å
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and. The slight variation of the RMSD observed over the simulation time could be at-
tributed to the receptor undergoing conformational changes. In short, the docking result of
Mpro-Quercetin 3-O-Neohesperidoside complex through specific interactions and energy
calculations showed that Quercetin 3-O-Neohesperidoside binding to Mpro is energetically
favorable. In addition, the stability and structural flexibility of the complex may be an
indication that Quercetin 3-O-Neohesperidoside may be repurposed as a potential inhibitor
of SARS-CoV-2.
4. Materials and Methods
4.1. ADME/Tox Analysis (Drug-Likeness)
The Schrodinger QikProp module, SwissADME (http://www.swissadme.ch/index.
php, accessed on 1 August 2021), and AdmetSAR (http://lmmd.ecust.edu.cn/admetsar1
/predict, accessed on 1 August 2021) were combined and used to analyze the physico-
chemical properties, water solubility, pharmacokinetics, lipophilicity, and drug-likeness, of
selected ligand. For toxicity, the Ames toxicity, carcinogenic properties, acute oral toxicity,
and rat acute toxicity were predicted.
4.2. Protein Preparation
An in silico molecular docking simulation approach was employed in this study.
Briefly, the SARS-CoV-2 main protease (Mpro), with the PDB ID: 6LU7, was retrieved
from the protein data bank (PDB) at https://www.rcsb.org/ (accessed on 1 August 2021).
During structural inspection with PDBSum, Mpro consisted of 306 amino acids, 84 water
molecules, and a co-crystalized ligand (N3). The Mpro resolution was 2.16 Å. The protein
preparation was carried out by UCSF Chimera prior to the docking simulation, and the
co-crystalized ligand (N3) was taken as the control. Water molecules, heteroatoms, and
co-crystallized solvent were removed and polar hydrogens and partial charges were added
to the structure protein structure during preparation. This was taken as the receptor.
4.3. Ligand Selection and Preparation
Five bioactive glycosylated flavonoids were identified based on the literature search and
previously reported by Cherrak et al. [49] as potential Mpro inhibitors. These ligands were
retrieved from PubChem at https://pubchem.ncbi.nlm.nih.gov/ (accessed on 1 August 2021)
and individually saved in the sdf file format. Preparation such as energy minimization among
other parameters was carried out to generate an accurate model that enumerates different
structural and chemical possibilities of these ligands by Molegro Molecular Viewer (MMV).
The outputs were individually saved in the mol2 file format prior to the docking calculation.
4.4. Molecular Docking Calculation
The interaction of the prepared ligands and N3 were investigated by docking them
into the active site of the receptor (Mpro) individually using the Autodock Vina software
with built-in UCSC Chimera. The 2D interaction diagram, poses, and their energies were
further computed.
4.5. ∆G Energy Calculation of the Docked Complexes
The ligand-binding energies (∆Gbind in kcal/mol) were calculated from the dock-
ing result using the Prime technology (MM/GBSA) module from Schrodinger. The
energies of the ligand–Mpro complex was estimated individually using the equation:
∆Gbind = Gcomplex − Gprotein − Gligand where ∆Gbind is the binding free energy and Gcomplex,
Gprotein, and Gligand are the free energies of complex, protein, and ligand, respectively [60,61].
In this study, only the free binding energies of the ligands were shown.
4.6. Molecular Dynamics Simulation (MDs)
This process of MDs was carried out by the Desmond module of the Schrodinger suite.
Briefly, a model system was built individually for the five complexes using the system
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builder module in maestro. Here, the model system was built to include Mpro, ligands,
explicit solvent, and counter ions (Na+ and Cl−). A value of 0.15 M is approximately the
physiological concentration of monovalent ions. The solvent model was predefined as
transferable intermolecular potential with 3 points (TIP3P) water molecules, box shape
was set as orthorhombic, box volume was calculated and minimized accordingly, while the
optimized potentials for liquid simulations (OPLS_2005) was used to prepare the force field.
The temperature and pressure of the model system were maintained at 300◦ Kelvin and
1.01325 bar, respectively [62]. Finally, the simulation was carried out at 100 nanoseconds
(ns). The output was analyzed by simulation interactions diagram module and MS-MD
trajectory analysis.
5. Conclusions
The contribution of biologically active molecules from natural sources has been in-
creasingly explored and exploited in the area of drug design using various techniques
for target identification and function attribution. Therefore, key protein identification as
a possible molecular target may by an interesting strategy for disease therapy and man-
agement. The current pandemic caused by SARS-CoV-2 has resulted in approximately
4 million mortalities with an increasing rate of infection globally. However, proteins such
as Mpro, among other targets, has been identified as a potential therapeutic target. The
Mpro of SARS-CoV-2 is involved in the processing of polyproteins that are translated from
the viral RNA. Therefore, the inhibition of Mpro could serve as an attractive drug target to
prevent disease transmission.
This study identified selected glycosylated flavonoids with reported biological activi-
ties as a potent inhibitor of SARS-CoV-2 Mpro. Through an in silico procedure, Quercetin
3-Rhamnoside was identified as the most SARS-CoV-2 Mpro inhibitor. The molecular dock-
ing result showed that these flavonoids displayed strong inhibitory activity against Mpro.
Quercetin 3-Rhamnoside interacted better than the reported mechanism-based inhibitor
(N3) of the SARS-CoV-2 Mpro. The MDs result reflected good dynamic behavior and
structural stability of Mpro complexed with all the ligands. Since substituted flavonoids
undergo reduced dietary modification in the gastrointestinal tract, this study hypothesized
that these classes of natural products may be useful in drug design or repurposed drugs
for disease therapy. In addition, target identification with bioactive molecules using both
docking calculation and molecular simulation approaches may suggest a pivotal source
of novel probe molecules against new and biologically relevant targets of deadly diseases
such as cancer and SARS-CoV-2.
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